WWhat Is TB-500?
TB-500 is a synthetic peptide fragment derived from thymosin beta-4.
The FDA identifies TB-500 as an N-terminally acetylated seven-amino-acid fragment corresponding to residues 17–23 of thymosin beta-4:
Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln
It is therefore not the same molecule as full-length thymosin beta-4.
That difference is one of the most important things to understand about TB-500 research.
Full-length thymosin beta-4 contains 43 amino acids and has a substantial research history.
TB-500 contains only a small portion of that sequence.
Yet online discussions frequently use “TB-500” and “thymosin beta-4” almost interchangeably.
Scientifically, they should be separated.
Why Are Researchers Interested in It?
Thymosin beta-4 attracted attention because of its unusually broad involvement in tissue repair.
Research has connected it with:
cell migration, wound healing, angiogenesis, inflammation, actin regulation, tissue remodeling, corneal repair, cardiac repair, and regenerative signaling.
The TB-500 fragment was developed from a biologically interesting region of thymosin beta-4 associated with cell migration and repair.
This led to the idea that a smaller synthetic fragment might retain some of the parent peptide’s regenerative properties.
That is the foundation of TB-500 research.
Thymosin Beta-4 vs. TB-500
This distinction needs to stay front and center.
Thymosin beta-4 is a naturally occurring 43-amino-acid peptide.
TB-500 is a synthetic seven-amino-acid fragment.
They are related.
They are not interchangeable.
The FDA specifically notes that many websites incorrectly refer to TB-500 as simply a synthetic version of thymosin beta-4, even though they are different substances. FDA reviewers also found that studies commonly submitted to support TB-500 actually involved full-length thymosin beta-4 instead.
So when you see claims that “TB-500 has been shown in human trials to heal wounds,” you have to ask:
Was the study really TB-500, or was it thymosin beta-4?
Very often, it was thymosin beta-4.
What Is Thymosin Beta-4?
Thymosin beta-4 is a naturally occurring intracellular peptide found in many tissues.
One of its best-known biological roles involves actin.
Actin is a structural protein essential for:
cell shape, cell movement, muscle biology, wound closure, and tissue remodeling.
Thymosin beta-4 binds monomeric G-actin and helps regulate the balance between free actin and polymerized actin filaments.
That may sound very cellular and abstract, but it has major implications for healing.
For damaged tissue to repair itself, cells often need to migrate into the injured area.
Actin remodeling helps make that movement possible.
Actin & Cell Migration
Actin is part of the cellular cytoskeleton.
Cells use it almost like an internal scaffolding and movement system.
During tissue repair, cells such as:
keratinocytes, endothelial cells, fibroblasts, and immune cells
need to move through damaged tissue.
Thymosin beta-4 helps regulate actin availability and cytoskeletal remodeling.
This connection between actin and cell migration is one of the strongest mechanistic reasons thymosin beta-4 became associated with wound healing.
The LKKTET Region
TB-500 is derived from a region of thymosin beta-4 containing the sequence LKKTETQ.
Research has suggested this central portion of thymosin beta-4 contributes to some of the peptide’s biological effects.
That is why researchers created synthetic fragments based on this region.
The hypothesis is that a smaller fragment might preserve certain repair-related signals while being easier to synthesize and study.
However, fragment biology can differ from the full-length parent peptide.
Removing most of a peptide can change:
binding, stability, distribution, receptor interactions, and overall biological activity.
That is why TB-500 needs its own direct evidence base.
Wound-Healing Research
Full-length thymosin beta-4 has some of its most interesting research in wound healing.
Animal studies have shown accelerated wound repair in skin and corneal injury models.
For example, thymosin beta-4 accelerated corneal re-epithelialization and reduced inflammatory-cell infiltration in a mouse model of severe corneal injury.
Other experimental work has demonstrated improved full-thickness skin wound healing.
This provides a strong biological foundation for interest in thymosin-based regenerative peptides.
But again:
these studies involved thymosin beta-4, not necessarily TB-500.
Human Wound Research
Thymosin beta-4 has also reached human clinical research.
A randomized, double-blind Phase 2 study involving 73 patients with venous stasis ulcers evaluated topical thymosin beta-4.
The treatment was reported to have an acceptable safety profile, and one tested concentration showed evidence suggesting accelerated wound healing in some patients.
That is meaningful.
It shows that thymosin beta-4’s wound-healing biology was strong enough to move beyond animals and into controlled human trials.
However, the study does not establish that injectable TB-500 produces the same effects.
Corneal Healing
The eye has been one of the most extensively studied areas for thymosin beta-4.
The cornea must repair itself rapidly while minimizing inflammation and scarring.
That makes it an excellent model for studying regenerative compounds.
Experimental research found that thymosin beta-4 could:
increase epithelial-cell migration, accelerate wound closure, reduce inflammatory-cell infiltration, and reduce inflammatory cytokine signaling.
Small compassionate-use research in nine patients with chronic neurotrophic corneal defects also reported substantial healing in several patients receiving topical thymosin beta-4.
Thymosin beta-4-based ophthalmic development has continued into clinical trials, although full FDA approval for that ophthalmic application has not yet been achieved.
Angiogenesis
Angiogenesis is the formation of new blood vessels.
Blood vessels are essential to tissue repair because they deliver:
oxygen, nutrients, immune cells, and growth signals.
Thymosin beta-4 has been associated with angiogenic signaling and endothelial-cell migration.
That may help explain why it performs well in several wound-healing models.
New vessel growth can be extremely useful in damaged tissue.
At the same time, angiogenesis is a tightly regulated process, and excessive or inappropriate vessel growth can also contribute to disease.
This makes the pathway powerful but biologically context dependent.
Tendon & Ligament Research
TB-500 is heavily marketed around tendon and ligament recovery.
The biological rationale is understandable.
Tendons and ligaments repair slowly because they have relatively limited blood supply compared with many other tissues.
A peptide associated with:
cell migration, angiogenesis, inflammation regulation, and tissue remodeling
would naturally attract attention in musculoskeletal research.
However, this is an area where marketing has moved considerably faster than clinical evidence.
Direct controlled human trials showing that TB-500 heals tendon or ligament injuries have not been established.
Much of the rationale comes from thymosin beta-4 biology and preclinical repair research.
Muscle Injury
Thymosin beta-4 research has also explored skeletal-muscle repair.
Muscle regeneration requires coordinated activity between:
satellite cells, inflammatory cells, connective tissue, vascular cells, and regenerating muscle fibers.
The actin-regulatory and cell-migration functions of thymosin beta-4 make muscle injury another plausible research area.
This is one reason TB-500 has become popular in athletic and recovery communities.
But direct clinical evidence for TB-500 improving human athletic recovery remains lacking.
Inflammation
Inflammation is necessary for wound healing.
Too little inflammation can impair repair.
Too much or prolonged inflammation can cause additional tissue damage.
Thymosin beta-4 appears to influence inflammatory signaling rather than simply suppressing it.
Corneal studies, for example, have reported reductions in inflammatory-cell infiltration and several inflammatory cytokine and chemokine signals.
This suggests part of its regenerative effect may come from helping shift injured tissue from the inflammatory stage toward repair.
Tissue Remodeling
Healing does not end when a wound closes.
Damaged tissue must then remodel.
That process can involve:
collagen deposition, extracellular-matrix organization, vascular remodeling, and replacement of damaged cells.
Thymosin beta-4 has been studied across several of these processes.
This broader repair profile helps explain why it has attracted interest beyond simple surface wounds.
Researchers are interested in whether it helps coordinate multiple stages of tissue recovery.
Cardiac Research
The heart became another major area of thymosin beta-4 research.
Experimental studies have investigated whether thymosin beta-4 can support cardiac-cell survival, blood-vessel growth, and repair following ischemic injury.
The biological rationale is especially compelling because heart tissue has limited regenerative capacity.
If injured cardiac tissue can be protected or supported during recovery, even modest effects could matter.
Human cardiovascular development has been pursued with full-length thymosin beta-4-related therapeutics, but this does not establish equivalent cardiovascular effects for TB-500.
Hair & Follicle Research
Thymosin beta-4 has also appeared in research involving hair follicles and skin appendages.
Hair growth requires coordinated epithelial and mesenchymal signaling along with vascular support.
Because thymosin beta-4 influences cell migration and angiogenesis, researchers have investigated whether it may also affect follicular biology.
This remains a much less established area than wound healing.
It is better viewed as an emerging research question rather than a proven hair-growth application.
Scar Formation
Another reason thymosin beta-4 attracts interest is tissue remodeling.
Researchers have explored whether the peptide may influence:
fibrosis, collagen organization, inflammation, and scar formation.
Ideally, regenerative medicine would not simply close a wound quickly.
It would restore tissue in a more organized and functional way.
That makes scar quality an important endpoint.
Current evidence is intriguing but heavily preclinical.
TB-500 & BPC-157
TB-500 and BPC-157 are frequently paired in research-peptide circles.
They are very different molecules.
BPC-157 is a 15-amino-acid synthetic peptide derived from a gastric-protein sequence and is studied heavily in preclinical tissue-repair and vascular research.
TB-500 is a seven-amino-acid thymosin beta-4 fragment.
The theoretical attraction of combining them comes from potentially complementary pathways.
BPC-157 is frequently associated with vascular, nitric-oxide, inflammatory, and tissue-repair signaling.
Thymosin beta-4-related biology emphasizes:
actin regulation, cell migration, angiogenesis, and wound repair.
The combination is biologically interesting.
But controlled human evidence validating a BPC-157/TB-500 combination is lacking.
TB-500 & GLOW/KLOW Blends
TB-500 also appears frequently in multi-peptide blends such as GLOW and KLOW.
Those products generally combine peptides intended to target different components of tissue repair.
The presence of TB-500 is usually intended to contribute the thymosin-related:
cell migration, angiogenesis, and regenerative component.
However, clinical evidence for the entire combined blend is different from evidence for each individual component.
A blend cannot automatically inherit every finding associated with full-length thymosin beta-4.
Is TB-500 the Same as Thymosin Beta-4?
No.
This is worth repeating because it is probably the single biggest source of confusion surrounding the compound.
The FDA identifies TB-500 as a seven-amino-acid N-terminally acetylated fragment of thymosin beta-4.
Full-length thymosin beta-4 contains 43 amino acids.
When a study says “thymosin beta-4,” it should not automatically be cited as a TB-500 study.
That doesn’t mean the thymosin beta-4 research is irrelevant.
It provides the scientific rationale for studying TB-500.
But it is parent-peptide evidence rather than direct fragment evidence.
Human Evidence for TB-500 Specifically
This is where the distinction becomes especially important.
In its 2026 scientific review, the FDA reported that it found no studies in which TB-500 itself had been administered to humans.
That is very different from full-length thymosin beta-4, which has been used in human clinical research.
So the evidence hierarchy currently looks something like this:
Full-length thymosin beta-4 biology: Strong.
Preclinical regenerative research: Strong and broad.
Human thymosin beta-4 research: Real, including wound and ophthalmic studies.
TB-500 fragment research: Much thinner.
Human TB-500 evidence: Not established in the FDA review.
This does not mean TB-500 lacks biological potential.
It means its reputation currently relies heavily on extrapolation from its parent peptide.
Evidence Snapshot
Full-length thymosin beta-4 mechanism: Strong.
Actin and cell-migration biology: Strong.
Wound-healing research: Strong preclinical evidence with some human clinical research for full-length thymosin beta-4.
Corneal repair: Particularly strong research area for thymosin beta-4.
Angiogenesis and tissue remodeling: Strong preclinical rationale.
Tendon, ligament, and muscle recovery: Biologically plausible and supported primarily by preclinical or parent-peptide evidence.
TB-500-specific human evidence: Extremely limited; FDA reported finding no human administration studies in its review.
FDA approval: TB-500 is not FDA approved.
What Do We Know?
The underlying thymosin beta-4 biology is genuinely compelling.
It is deeply involved in:
actin regulation, cell migration, wound repair, inflammation, angiogenesis, and tissue remodeling.
Full-length thymosin beta-4 has produced positive findings in numerous experimental injury models and has reached human clinical research.
That gives the thymosin pathway a real scientific foundation.
TB-500 itself represents an attempt to capture some of that biology in a smaller synthetic fragment.
The problem is simply that the fragment has not yet accumulated the same body of evidence as its parent peptide.
What Are Researchers Still Trying to Determine?
The most obvious research need is surprisingly simple:
study TB-500 itself.
Researchers need direct studies examining:
pharmacokinetics, biological activity, tissue distribution, wound healing, tendon recovery, muscle repair, inflammatory effects, optimal dosing, immunogenicity, and long-term safety.
They also need head-to-head comparisons between:
TB-500 and full-length thymosin beta-4.
That would tell us which effects of thymosin beta-4 are preserved by the smaller fragment and which require the complete 43-amino-acid molecule.
Until those studies exist, separating the molecules is essential.
Research & Regulatory Status
TB-500 is not an FDA-approved drug.
In July 2026, the FDA’s Pharmacy Compounding Advisory Committee reviewed TB-500-related bulk drug substances for potential use in wound healing.
FDA reviewers emphasized several important limitations.
They found no human studies administering TB-500 itself and raised concerns involving peptide aggregation, impurities, characterization, and potential immunogenicity in compounded products.
The FDA substance database recognizes TB-500’s chemical identity, but inclusion in that database does not mean the compound has been reviewed or approved as a medication.
Your Pep Resource Takeaway
TB-500 is a perfect example of why peptide names and molecular identity matter.
The biological story behind it is exciting.
Thymosin beta-4 has a substantial research history involving:
wound healing, actin regulation, cell migration, angiogenesis, inflammation, corneal repair, and tissue remodeling.
There is even human clinical research involving full-length thymosin beta-4.
But TB-500 is only a seven-amino-acid fragment of that 43-amino-acid peptide.
That means the impressive thymosin beta-4 literature should be viewed as the reason TB-500 is worth studying—not proof that the fragment produces all of the same effects.
That does not make TB-500 uninteresting.
Quite the opposite.
It gives researchers a very specific question:
Can a small fragment preserve the most useful regenerative properties of thymosin beta-4?
If future direct studies show that it can, TB-500 could become a particularly interesting tool in regenerative and wound-healing research.
For researchers interested in tissue repair, wound healing, tendons, ligaments, muscle recovery, cell migration, angiogenesis, actin biology, inflammation, and regenerative medicine, the thymosin beta-4/TB-500 pathway remains one of the most fascinating areas in peptide research.
Research Areas / Search Keywords
TB-500, TB500, thymosin beta-4 fragment, thymosin beta 4 fragment, thymosin beta-4, thymosin beta 4, Tβ4, Tbeta4, Ac-LKKTETQ, LKKTETQ, thymosin peptide, regenerative peptide, repair peptide, recovery peptide, wound healing peptide, wound healing research, tissue repair, tissue regeneration, regenerative medicine, tendon research, tendon healing, tendon injury, ligament research, ligament healing, muscle recovery, muscle repair, skeletal muscle research, soft tissue injury, sports recovery research, injury recovery, actin, G-actin, actin binding, cytoskeleton, cell migration, keratinocyte migration, endothelial cell migration, fibroblast research, angiogenesis, blood vessel growth, vascular repair, inflammation research, anti-inflammatory peptide research, wound inflammation, collagen research, extracellular matrix, tissue remodeling, scar research, fibrosis research, corneal healing, corneal wound healing, eye repair research, cardiac repair, heart injury research, myocardial research, hair follicle research, hair growth research, TB-500 vs thymosin beta-4, TB-500 vs BPC-157, BPC-157 TB-500, Wolverine peptide research, GLOW peptide blend, KLOW peptide blend, experimental peptide, research peptide, peptide science.
Educational Disclaimer
This profile is provided for educational and research-information purposes only. TB-500 is not the same molecule as full-length thymosin beta-4, and findings from thymosin beta-4 studies should not automatically be interpreted as direct evidence for TB-500. Full-length thymosin beta-4 has meaningful preclinical and some human clinical research, while FDA reviewers reported in 2026 that they had not identified human studies administering the TB-500 fragment itself. TB-500 is not an FDA-approved medication, and unapproved research or compounded products should not be assumed to have the identity, purity, safety, or biological performance of materials used in published thymosin beta-4 research.